Lumos Diagnostics Holdings Limited (ASX:LDX)

Australia flag Australia · Delayed Price · Currency is AUD
0.155
+0.005 (3.33%)
Apr 29, 2026, 2:59 PM AEST
474.07%
Market Cap 138.40M
Revenue (ttm) 18.31M
Net Income (ttm) -13.88M
Shares Out 922.70M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE 0.15
Dividend n/a
Ex-Dividend Date n/a
Volume 3,541,170
Average Volume 6,672,374
Open 0.145
Previous Close 0.150
Day's Range 0.145 - 0.160
52-Week Range 0.024 - 0.330
Beta 0.81
RSI 29.19
Earnings Date Apr 20, 2026

About ASX:LDX

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platfor... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2018
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol LDX
Full Company Profile

Financial Performance

In fiscal year 2025, ASX:LDX's revenue was $12.40 million, an increase of 11.40% compared to the previous year's $11.13 million. Losses were -$7.18 million, -16.40% less than in 2024.

Financial numbers in USD Financial Statements

News

There is no news available yet.